Longeveron (LGVN) Short-term Investments (2021 - 2024)
Longeveron's (LGVN) quarterly Short-term Investments came in at $351000.0 in Q1 2024, down 12.25% year-on-year from $400000.0 in Q2 2023, and down 14.81% quarter-over-quarter from $412000.0 in Q4 2023.
Longeveron (LGVN) Short-term Investments (2021 - 2024) Analysis & Trends
Longeveron's Short-term Investments history runs 4 years deep, the most recent figure standing at $351000.0 for Q1 2024.
- On a quarterly basis, Short-term Investments fell 12.25% year-over-year to $351000.0 in Q1 2024; TTM through Mar 2024 was $351000.0, a 12.25% decrease from a year earlier, with the FY2023 full-year figure at $412000.0, down 95.5% from the prior year.
- Short-term Investments fell to $351000.0 in Q1 2024 per LGVN's latest filing, from $412000.0 in the prior quarter.
- Across five years, Short-term Investments topped out at $9.4 million in Q4 2021 and bottomed at $351000.0 in Q1 2024.
- The 4-year median for Short-term Investments is $2.0 million (2023), against an average of $3.9 million.
- Across the five-year window, Short-term Investments dropped 2.45% in 2022 and plunged 95.5% in 2023, its largest moves.
- Year by year, Short-term Investments stood at $9.4 million in 2021, then decreased by 2.45% to $9.2 million in 2022, then plunged by 95.5% to $412000.0 in 2023, then slipped by 14.81% to $351000.0 in 2024.
- Per Business Quant, the three latest LGVN Short-term Investments figures stand at $351000.0 (Q1 2024), $412000.0 (Q4 2023), and $2.0 million (Q3 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 351,000.00 |
| Dec 31, 2023 | 412,000.00 |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 5.91 Mn |
| Mar 31, 2023 | 400,000.00 |
| Dec 31, 2022 | 9.16 Mn |
| Dec 31, 2021 | 9.39 Mn |